The challenge of <i>Helicobacter pylori</i> resistance to antibiotics: the comeback of bismuth-based quadruple therapy

Mégraud, Françis

doi:10.1177/1756283x11432492

Cited by 119 publications

(82 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Throughout the past 20 years, the endorsed irst-line therapy for H. pylori abolition contained the mixture of the antibiotics amoxicillin and clarithromycin with omeprazole, a proton pump cell inhibitor. The upsurge of H. pylori resistance to these antibiotics (chiely to clarithromycin) completes this therapy which is a non-atractive choice in new ages [27]. Additional action plans have arose to competition H. pylori infections, which comprise the usage of bismuth salts joint with a proton pump cell inhibitor [28].…”

Section: Enzyme Inhibitors and Activators 168mentioning

confidence: 99%

Natural Products as a Potential Enzyme Inhibitors from Medicinal Plants

Rauf¹,

Jehan²

2017

Enzyme Inhibitors and Activators

View full text Add to dashboard Cite

Enzyme inhibitory agents are atractive because of their application in treating diferent ailments. The absence of enzymes produce a number of diseases. Medicinal plants are a rich source of producing secondary metabolites which showed broad-spectrum enzyme inhibitory potential. The position of enzyme inhibitors as new drugs is vast since these compounds have been used for the treatment of various physiological disorders. Bioactive secondary metabolites can deliver excellent pharmacophore paterns for drugs related to numerous illnesses. This book chapter is planned to document the enzyme inhibitory potential of natural compounds, medicinal plant extract, and its isolated compounds.

show abstract

Section: Enzyme Inhibitors and Activators 168mentioning

confidence: 99%

Natural Products as a Potential Enzyme Inhibitors from Medicinal Plants

Rauf¹,

Jehan²

2017

Enzyme Inhibitors and Activators

View full text Add to dashboard Cite

show abstract

“…Increasing the duration of therapy to 10 or 14 days is suggested; however, 10 or 14 day use has controversial results and may increase antibiotic resistance [50]. To overcome this issue, sequential, concomitant or quadruple approaches have been alternatively used as a first line therapy [6,51]. Recently, studies on a triple therapy containing a potassium-competitive acid blocker (P-CAB) (vonoprazan 20 mg+amoxicillin 750 mg+clarithromycin 200 mg/ metronidazole 200 mg bid*7d) compared to a PPI-based low dose clarithromycin triple therapy showed promising eradications rates of 89-98% [52,53].…”

Section: Standard Therapymentioning

confidence: 99%

Helicobacter pylori infection: A recent approach to diagnosis and management

Rana¹,

Wang²,

Li³

et al. 2017

J. Biomed

View full text Add to dashboard Cite

Helicobacter pylori infection is the most common infection worldwide and is associated with simple dyspepsia, heartburn and peptic ulcer diseases, most commonly leading to upper gastrointestinal bleeding and, ultimately, to the severe complication of gastric malignancy. Ninety percent of duodenal ulcers and 70% of gastric ulcers are associated with helicobacter pylori infections. Noninvasive methods, such as the urea breath test (UBT-13C or 14C) and fecal antigen test (FAT), have high sensitivity and specificity for the diagnosis of H. pylori. However, 4-6 weeks of anti-secretary drugs (proton pump inhibitor) prior to testing can lead to false negative results. Invasive methods have benefits over noninvasive methods in the case of peptic ulcer diseases by taking samples for culture to determine their sensitivities and to stage disease progression to malignant transformation. Initially, standard triple regimen was the choice for treatment worldwide. However, high antibiotic resistances in various geographical regions have recently made standard quadruple therapy (bismuth-based) the preferred treatment. Recent studies have shown the promising benefits of 10-14 days of sequential and concomitant quadruple therapies as the first line option in high drug resistance areas, in cases of multidrug resistance or in prior treatment failure cases. Levofloxacin-based triple therapy, furazolidone-based regimens, and recent hybrid or rescue therapies are also beneficial towards the eradication of H. pylori infection as a second or third line therapy. Additionally, the use of probiotics and phytomedicines improve eradication rates when used with triple or quadruple therapies.

show abstract

“…Approximately 20% of H. pylori strains are proved to be clarithromycin resistant. As a consequence, it is strongly recommended to attempt an eradication by quadruple therapy using a bismuth salt, tetracycline, metronidazole and PPI instead of triple therapy using PPI, clarithromycin and amoxicillin [40]. H. pylori antibiotic therapy can lead to complete GML remission in 77.5-94% of patients [16].…”

Section: Gastric Malt Lymphoma Treatmentmentioning

confidence: 99%